XOMA Royalty (NASDAQ:XOMA) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of XOMA Royalty (NASDAQ:XOMA) from a buy rating to a hold rating in a research note published on Saturday morning.

A number of other equities analysts also recently issued reports on XOMA. Weiss Ratings raised XOMA Royalty from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday. Zacks Research lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.50.

XOMA Royalty Stock Performance

NASDAQ:XOMA opened at $32.64 on Friday. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.88 and a quick ratio of 4.88. The firm has a market capitalization of $394.55 million, a PE ratio of -21.06 and a beta of 1.12. The business’s fifty day moving average price is $35.80 and its 200 day moving average price is $30.18.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%.The business had revenue of $9.35 million for the quarter, compared to analyst estimates of $11.47 million. On average, sell-side analysts anticipate that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Thomas M. Burns sold 4,330 shares of XOMA Royalty stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the completion of the transaction, the chief financial officer owned 30,079 shares of the company’s stock, valued at $1,082,543.21. The trade was a 12.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Nuveen LLC purchased a new position in shares of XOMA Royalty in the 1st quarter worth about $286,000. Stonepine Capital Management LLC increased its position in XOMA Royalty by 3.3% during the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock worth $2,587,000 after purchasing an additional 4,113 shares in the last quarter. CM Management LLC raised its holdings in XOMA Royalty by 16.4% in the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock valued at $1,276,000 after buying an additional 9,000 shares during the period. Deutsche Bank AG raised its holdings in XOMA Royalty by 5,087.9% in the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 6,309 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of XOMA Royalty in the second quarter worth $370,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.